logo
Select company
Select metric
23.91%Cash to Assets Ratio
VS
Market
79
Sector
52
Industry
39
History
23
$ 8.3Close
$ 6.41 - $ 16.8 52-Week Range
Ticker Information

Ticker

GYRE

Company Name

GYRE THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

GYRE THERAPEUTICS INC - Cash to Assets Ratio Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

GYRE - Cash to Assets Historical data
DateTotal AssetsCash and EquivalentsCash to Assets Ratio
6/30/2025$ 152.65M$ 36.49M23.91%
3/31/2025$ 129.79M$ 15.04M11.59%
12/31/2024$ 125.41M$ 11.81M9.42%
9/30/2024$ 125.24M$ 15.87M12.67%
6/30/2024$ 120.93M$ 16.1M13.31%
3/31/2024$ 122.01M$ 29.79M24.41%
12/31/2023$ 116.54M$ 33.51M28.75%
9/30/2023$ 9.96M$ 2.23M22.36%
6/30/2023$ 12.39M$ 6.92M55.86%
3/31/2023$ 18.75M$ 8.1M43.19%
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • GYRE THERAPEUTICS INC's latest trailing twelve months (TTM) Cash to Assets stands at 22.29%.
  • Over the past 5 years, GYRE THERAPEUTICS INC's average Cash to Assets has been 46.22%.
  • The median Cash to Assets for GYRE THERAPEUTICS INC during this period was 37.6%
  • GYRE THERAPEUTICS INC reached its highest Cash to Assets over the past 5 years at 90.43%.
  • The lowest Cash to Assets recorded by GYRE THERAPEUTICS INC in the same timeframe 9.42%

GYRE THERAPEUTICS INC's Cash to Assets vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

Cash to Assets Benchmarks
CompanyCash to Assets
PHAT : PHATHOM PHARMACEUTICALS INC 60.92%NAGE : NIAGEN BIOSCIENCE INC 66.07%ANAB : ANAPTYSBIO INC 13.21%TBPH : THERAVANCE BIOPHARMA INC 66.37%URGN : UROGEN PHARMA LTD 45.03%CRMD : CORMEDIX INC 63.07%NRIX : NURIX THERAPEUTICS INC 15.2%ZVRA : ZEVRA THERAPEUTICS INC 18.62%KURA : KURA ONCOLOGY INC 12.01%SAGE : SAGE THERAPEUTICS INC 16.3%

Definition of Cash to Assets Ratio

[Calculation] The Cash to Assets Ratio expresses a company’s cash and cash equivalents [CashnEq] as a percentage of total [Assets].
CashnEq / Assets
(=) Cash to Assets
Cash to Assets for GYRE THERAPEUTICS INC is calculated as follows: CashnEq [ $ 24.92M ] / Assets [ $ 111.8M ]
(=) Cash to Assets [ 22.29% ]

GYRE - Cash to Assets Ratio, Last 5 years

9.42%

Minimum

Dec 31, 2024

90.43%

Maximum

Jun 30, 2022

46.22%

Average

37.6%

Median

Cash to Assets Benchmark Analysis

The chart above depicts the distribution of Cash to Assets for companies in the Total Stock Market. The average Cash to Assets of the companies is 9.84% with a standard deviation of 9.62%.
The following table provides additional summary stats:
Cash to Assets in the Market:
filtered constituents3.95K
min0%
max40.92%
average9.84%
median6.44%
std9.62%